Market Overview - The Legal Cannabis Market has grown from USD 33.52 billion in 2024 to USD 42.91 billion in 2025, with a projected value of USD 144.18 billion by 2030, reflecting a compound annual growth rate (CAGR) of 27.52% [2][11]. - The market evolution is driven by legislative changes, consumer behavior, and technological advancements [2]. Industry Dynamics - Legislative changes and increasing consumer acceptance have led to a diverse range of products, including extracts and edibles, while regulatory bodies are enhancing quality control measures [3]. - Vertical integration and partnerships are essential for achieving scale and distribution advantages, with advances in cultivation improving yields and consistency [4]. - Federal developments are fostering optimism regarding interstate commerce and harmonized licensing and taxation frameworks [5]. Investment Trends - There is a noticeable shift towards ancillary services and strategic mergers and acquisitions, which are reshaping competitive landscapes and refining value creation across the supply chain [6]. - Decision-makers are gaining strategic insights to identify opportunities amid evolving consumer preferences and technological advancements [6]. Tariff Impact - New tariff structures in 2025 have increased costs for cultivation and processing, leading to reassessments of manufacturing locations and supplier networks [8]. - Retailers are facing margin pressures due to increased duties on imported machinery and packaging components, often passing costs to consumers [9]. - Regional operators are diversifying sourcing strategies to mitigate future tariff effects, fostering collaborative partnerships to maintain resilience [9]. Key Report Attributes - The report spans 193 pages, covering the forecast period from 2025 to 2030, with an estimated market value of USD 42.91 billion in 2025 and a forecasted value of USD 144.18 billion by 2030 [11].

TORONTO, June 17, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual and special meeting (the “Meeting”) of holders of common shares ("Shareholders") held today. There were 146 Shareholders represented virtually or by proxy at the Meeting holding an aggregate of 210,726,733 common shares, representing 50.76% of Me ...

Core Viewpoint - MediPharm Labs Corp. responds to a misleading press release from Apollo Technology Capital Corporation regarding the results of its annual and special meeting of shareholders, emphasizing that the meeting has not yet occurred and results are not available [1][2]. Company Overview - MediPharm Labs, founded in 2015, specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and advanced derivative products, utilizing a Good Manufacturing Practices certified facility [3]. - The company has invested in a research-driven team and state-of-the-art technology to deliver precision-dosed cannabis products to both domestic and international medical markets [3]. Regulatory Milestones - In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, making it the only company in North America with a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids [4]. - This GMP license is a crucial step towards the company's foreign drug manufacturing site registration with the US FDA [4]. Recent Acquisitions - In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded its reach to medical patients in Canada and internationally through various platforms and clinics [5]. - The acquisition included Harvest Medical Clinics in Canada, which provides consultations for medical cannabis education and prescriptions [5]. Compliance and Operations - The company operates in compliance with all applicable laws in the countries where it conducts business [6].

TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that leading independent proxy voting and corporate governance advisory firm Glass, Lewis & Co. LLC (“Glass Lewis”) published a report on June 12, 2025 recommending that MediPharm shareholders vote the GREEN Proxy or voting instruction form FOR the Company’s nominees for the Board of Directo ...

Shareholders Urged to Vote for Proven Strategy and Team, Reject Dissident’s Inadequate Plan and NomineesTORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm,” the “Company,” “we” or “us”), a pharmaceutical company specialized in precision-based cannabinoids, today reminded its shareholders that the deadline is approaching to cast your vote for the upcoming Annual and Special Meeting of Shareholders on June 16, 2025 (the “Meeting”). All votes must ...

TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that the Superior Court of Justice – Ontario (Commercial List) (the “Court”) has fully dismissed the application (CV-25-00743454-00CL) (the “Application”) issued by Apollo Technology Capital Corporation (“Apollo”) and Nobul Technologies Inc. (together with Apollo, the “Applicants”) against t ...

VANCOUVER, British Columbia, June 09, 2025 (GLOBE NEWSWIRE) -- LEEF Brands Inc. (CSE: LEEF) (OTCQB: LEEEF) (“LEEF” or the “Company”), a premier California and New York extraction company, today announced a significant development as it begins to expand nationally. LEEF Closes on New York Type 1 Cannabis Processor LicenseLEEF has officially closed on the acquisition of a Type 1 Cannabis Processor License in New York. This is a plant-touching license that allows the Company to engage in extraction, blending, ...

TORONTO, May 23, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (“MediPharm”, the “Company”, or “we”), a pharmaceutical company specialized in precision-based cannabinoids, today provided its shareholders with information related to three of the six directors (the “Dissident Nominees”) nominated by Apollo Technology Capital Corporation (“Apollo”) to stand for election at MediPharm’s Annual and Special Meeting of Shareholders on June 16, 2025. All dollar figures in this news release are in U.S. do ...

TORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the removal of all conditions precedent, related to its previously-announced agreement (the “Purchase Agreement”) for the sale of MediPharm’s facility in Hope, BC, (“Hope Facility”) to Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) for $4.5 million in cash (the “Transaction”). With these conditions now met, ...